Andexanet alfa

Andexanet alfa
Clinical data
Trade names	Andexxa, Ondexxya, others
Other names	Coagulation factor Xa (recombinant), inactivated-zhzo, PRT06445, r-Antidote, PRT4445
AHFS/Drugs.com	Monograph
License data	US DailyMed: Andexanet_alfa;
Pregnancy; category	AU: B2; ;
Routes of; administration	Intravenous injection
ATC code	V03AB38 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: WARNINGRx-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	5 h to 7 h
Identifiers
	IUPAC name Andexanet alfa;
CAS Number	1262449-58-0;
IUPHAR/BPS	7576;
DrugBank	DB14562;
ChemSpider	none;
UNII	BI009E452R;
KEGG	D11029;
ChEMBL	ChEMBL3301583;

Andexanet alfa, sold under the brand name Andexxa among others, is an antidote for the medications rivaroxaban and apixaban, when reversal of anticoagulation is needed due to uncontrolled bleeding.^[8] It has not been found to be useful for other factor Xa inhibitors.^[9] It is given by injection into a vein.^[9]

Common side effects include pneumonia and urinary tract infections.^[9] Severe side effects may include blood clots, heart attacks, strokes, or cardiac arrest.^[9] It works by binding to rivaroxaban and apixaban.^[9]

It was approved for medical use in the United States in May 2018.^[8] It was developed by Portola Pharmaceuticals.^[10]

^ ^a ^b "Andexxa APMDS". Therapeutic Goods Administration (TGA). 12 July 2023. Retrieved 10 September 2023.
^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^ "Andexxa (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 28 July 2023. Archived from the original on 11 September 2023. Retrieved 10 September 2023.
^ "AusPAR: Andexxa". Therapeutic Goods Administration (TGA). 19 December 2023. Retrieved 31 March 2024.
^ "Details for: Ondexxya". Health Canada. 16 June 2023. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
^ "Summary Basis of Decision (SBD) for Ondexxya". Health Canada. Retrieved 11 December 2023.
^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-08-30]". Health Canada. 26 October 2023. Archived from the original on 3 January 2024. Retrieved 3 January 2024.
^ ^a ^b ^c "Andexxa- andexanet alfa injection, powder, lyophilized, for solution". DailyMed. 21 September 2020. Archived from the original on 18 November 2020. Retrieved 12 November 2020.
^ ^a ^b ^c ^d ^e "Andexxa Monograph for Professionals". Drugs.com. Archived from the original on 19 December 2018. Retrieved 19 December 2018.
^ Dolgin E (March 2013). "Antidotes edge closer to reversing effects of new blood thinners". Nature Medicine. 19 (3): 251. doi:10.1038/nm0313-251. PMID 23467222. S2CID 13340319.